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INVESTIGATING MEDICAL EXAMINERS’ PRACTICES: GENETIC EVALUATION FOR
FATAL ACUTE AORTIC DISSECTION

Bradley Philip Power, BA

Advisory Professor: Krista J. Qualmann, MS, CGC
Acute thoracic aortic dissection (TAD) is a life-threatening event with a hereditary component.
Currently, pathogenic variants in 11 genes associated with aortic aneurysm and dissection predispose to a
heritable form of disease thereby conferring an increased risk for TAD. Genetic testing plays a pivotal
role not only in diagnosis, but also in risk stratification for relatives and medical management to prevent
premature death from dissection. Due to its high fatality rate, medical examiners and coroners (ME/Cs)
may be the first to identify TAD cases and initiate genetic testing for the decedent and at-risk relatives.
ME/Cs were surveyed using three clinical vignettes detailing two cases of early-onset TAD, one with
features of Marfan syndrome and another without, and a later onset TAD case. Sixty respondents
reported their likelihood to complete various actions related to their level of suspicion for a genetic cause
and recommendations for relatives (e.g. collect sample for testing, recommend imaging for relatives).
Additionally, respondents were queried about current practices and perceived barriers regarding genetics
evaluations for TAD. Reported practices were compared to recommendations established by the National
Association of Medical Examiners (NAME). Respondents were significantly more likely to perform all
proposed actions in the two early-onset cases versus the late-onset, non-syndromic case. ME/C’s were
significantly more likely to speak with the decedent’s next-of-kin (NOK) about increased TAD risk and
refer for genetic counseling in the early-onset syndromic vignette compared to early-onset nonsyndromic case. Experience, approximated by the number of TAD cases seen at practicing institution,
did not impact respondents’ choices, but access to a genetic counselor did. Cost of genetic testing was
the most frequently reported barrier, followed by contacting NOK. Alignment with NAME guidelines
varied, converging around sample collection, but diverging when communicating with NOK. Our results
suggest that ME/Cs recognize the utility of postmortem genetic testing and the clinical risk factors for
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hereditary TAD. However, ordering genetic testing and recommending aortic imaging for at-risk
relatives is inhibited by concerns regarding cost of genetic testing or access to NOK. Increasing ME/C’s
access to genetic counseling services will be important for postmortem genetics evaluations in this
population.
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Introduction
Acute thoracic aortic dissection (TAD) is a life-threatening event associated with a high fatality
rate. Death occurs in up to 50% of affected individuals within the first 24 hours after symptom onset,
most commonly from pericardial tamponade (1-3). Incidence of TAD is likely underestimated because
up to 40% of individuals do not survive long enough to reach the hospital. However, it is estimated to
range from 2/100,000/year to 6/100,000/year, reflecting the magnitude of individuals impacted. Due to
the incidence and high disease fatality rate outside the hospital, medical examiners may be the first to
make the diagnosis on autopsy (4).
It has been established for many years that Marfan syndrome, due to mutations in a single gene,
FBN1, confers a high risk for TAD. Further, studies have shown that up to 20% of individuals with
thoracic aortic aneurysm or dissection (TAAD) who have not been diagnosed with genetic syndrome,
report a family history of TAAD (5, 6). Expert review of genes linked to hereditary TAAD in 2018 using
a validated ClinGen framework determined that highly penetrant variants in FBN1 and ten other genes
lead to a heritable form of TAAD.(7). Burgeoning evidence demonstrates that the identification of such
variants can be used to guide the treatment and management of TAD survivors and identify relatives who
are at risk for dissection, thus preventing further fatalities (8). The majority of diagnostic genetic testing
for TAD is completed via a multigene panel approach where the genes known to be associated with TAD
are collectively assayed on a next-generation sequencing platform. The yield of genetic testing to
identify the causative variant in an affected individual varies based on the presence of a family history of
TAAD, syndromic physical features, and age of dissection onset. For example, 9.3% of early-onset (≤ 56
years) TAD cases with no family history have an identifiable genetic cause, while >30-40% of cases with
a positive family history harbor a pathogenic variant in a known gene (9-11). Further, if syndromic
features characteristic of Marfan or Loeys-Dietz syndromes are present, the likelihood of determining the
genetic cause of TAD is even higher. However, classic syndromic features are not present in all
individuals with Marfan syndrome (FBN1) or Loeys-Dietz syndrome-related genes (TGFBR1, TGFBR2,
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SMAD3, TGFB2) (12, 13). Despite the diagnostic yield and clinical implications of genetic testing, its
use by medical examiners and coroners (ME/Cs) for cases of TAD has not been investigated.
The National Association of Medical Examiners (NAME) established recommendations in 2013
to facilitate postmortem genetic testing and evaluation in cases with an increased suspicion for genetic
etiologies, including TAD (14). Additionally, the American Heart Association and American College of
Cardiology (AHA/ACC) guidelines for the diagnosis and management of patients with thoracic aortic
disease advise on the utility of genetic testing for individuals with TAAD and recommend aortic imaging
for first-degree relatives of all individuals with thoracic aortic disease (15). With over 2,000 ME/C
offices in the United States, ME/C’s are in a unique position to investigate genetic diagnoses in cases of
fatal TAD. Genetic diagnosis in the decedent can lead to predictive genetic testing in other family
members, which may inform them of their risk status, prompt relevant screening, and improve clinical
outcomes for these families (16). Furthermore, data shows that hypertension is a major risk factor for
aortic dissection and autopsy studies may reveal how pathogenic variation in aortic disease genes may
operate in conjunction with environmental risk factors to lead to aortic events, something that can help
inform clinical care and management for the wider patient base (3, 4, 17).
Here we aimed to evaluate: 1) ME/Cs’ genetic testing and counseling practices for cases of TAD
diagnosed at the time of autopsy, 2) identify barriers to providing genetic services in the ME/C setting,
and 3) compare ME/Cs’ reported practices to the NAME’s recommendations for postmortem genetic
testing. Aims were assessed by administering online surveys to ME/Cs though the NAME and the
International Association of Coroners and Medical Examiners (IACME) membership listservs. Using
three clinical vignettes, we report how often and in what clinical scenarios ME/Cs collect samples and/or
order post-mortem genetic testing for TAD cases, describe the clinical features contributing to their
decision to pursue a genetics evaluation, and identify whether reported practices are in accordance with
established NAME guidelines.
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Methods
Study respondents were members of NAME and/or IACME. The study was approved by the
University of Texas Health Science Center at Houston Institutional Review Board (HSC-MS-01-251).
The survey was distributed to an estimated 1,337 and 1,100 professionals through the NAME and
IACME e-mail list-servs, respectively. Respondents were asked to complete the survey between
October 2019 and February 2020. English-speaking ME/Cs who actively perform autopsies were eligible
to participate in the study. Progression past the first question of the survey served as an
acknowledgement of informed consent.
The survey, developed using Qualtrics XM software, consisted of 59 questions and was
estimated to take 15 minutes to complete. The complete survey is available in Appendix C. Questions
were designed to collect demographic information and evaluate three primary topics: 1) ME/Cs’
recognition of the genetic contribution to TAD using three vignettes with different clinical presentations,
2) access to clinical genetic services and perceived barriers to genetic testing, and 3) ME/Cs’ current
practices regarding biospecimen collection and storage, and their interactions with family members. The
first topic was assessed by employing a visual analog scale (VAS) to capture how likely the respondent
was to perform a follow-up action for each of the three clinical vignettes (questions 1-7) and how
suspicious they were for a genetic diagnosis (question 8) in the context of a fatal TAD (Table 1).
Possible VAS scores ranged from 0 to 100, with 0 reflecting that the respondent would “never”
perform the given task or had “no suspicion” for a genetic diagnosis and 100 reflecting that the
respondent would “always” perform the specified action or was certain of a “definite genetic cause .”
Complete descriptions of the vignettes can be found in Table 1. Vignette 1 described a 30-year-old male
decedent with syndromic features characteristic of Marfan syndrome (18); Vignette 2 described a 72year-old male decedent with no syndromic physical features; and Vignette 3 described a non-syndromic
27-year-old male decedent with TAD. All respondents were asked questions regarding the second survey
topic. Questions pertaining to the third topic were not asked to all respondents. The extent of the
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questions asked to respondents was based on their responses to two questions, namely, if they collect
samples for genetic testing and if they order genetic testing.
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Table 1. Clinical Vignettes and accompanying Visual Analog Scale Questions
Vignette 1: A 30-year-old man dies suddenly at home. On post -mortem exam,
he is 6' 8", thin, has a mild pectus carinatum and long, thin fingers. His medical
record notes scoliosis. On autopsy, he is found to have type A aortic dissection
with pericardial tamponade.
Vignette 2: A 72-year-old man complains of chest pain and dies suddenly in a
restaurant. On post-mortem exam, he is 5' 9" with average body habitus. His
medical record indicates her was healthy except mild hypertension treated with
one drug. On autopsy, he is found to have type A aortic dissection with
pericardial tamponade.
Vignette 3: A 27-year-old man collapses and dies suddenly after a run. On
post-mortem exam, he is 5' 9", average body habitus, and the family reports he
was healthy and had no medical problems. On autopsy, he is found to have type
A aortic dissection with pericardial tamponade.

Visual analog scale prompt
On a scale from "I would always perform that task" to "I would never perform
that task," how likely would you be to carry out the following tasks for this
case?

Question 1) I or someone in my office would collect a biological sample from
the deceased person that could be used for genetic testing.
Question 2) I or someone in my office would attempt to collect additional
family history from relatives.
Question 3) I or someone in my office would provide information to the
deceased person’s relatives about an increased risk for thoracic aortic
aneurysms and dissections.
Question 4) I or someone in my office would recommend thoracic aortic
imaging for first degree relatives of the deceased person.
Question 5) I or someone in my office would order genetic testing for the
deceased person.
Question 6) I or someone in my office would refer the deceased person’s
relatives for cardiology evaluation.
Question 7) I or someone in my office would refer the deceased person’s
relatives for genetic counseling.
Question 8) Based on the information provided, how suspicious are you that
there is a genetic cause for Vignette #?
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Legend: Respondents were asked to read three clinical vignettes and respond to questions using a
visual analog scale prompt. Respondents used a sliding scale from 0-100 with demarcations for 0%
(Never), 25%, 50%, 75%, and 100% (Always) to indicate how likely they would be to perform the
action listed (questions 1-7) or how suspicious they were for a genetic cause (question 8) for each
vignette.
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Survey responses were collected into Microsoft Excel and statistical analyses were performed
using STATA v.13.1. Analyses were performed using an α level of 0.05. Data were not normally
distributed; therefore, non-parametric tests were used and medians and inter-quartile ranges (IQR) are
reported. Wilcoxon signed-rank test was used to evaluate the difference in responses for each individual
respondent between vignettes. Mann-Whitney U test was used to assess differences in responses between
respondents who do and do not order genetic testing and between those with and without access to a
genetic counselor. Kruskal-Wallis test with post-hoc Dunn test was used to assess differences in
participant responses based on the number of cases of thoracic aortic dissections seen in 1 year and 5
years. Fischer’s exact test was used to assess differences between perceived barriers in respondents with
and without access to a genetic counselor and between those who do and do not order genetic testing.
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Results
Characteristics of survey respondents
Between October 16, 2019 and February 5, 2020, 97 survey responses were collected. After
excluding 28 responses due to unknown or lack of involvement in autopsies, 69 remained. A total of
60 respondents were included in the analysis for this study after excluding 9 additional responses due
to lack of progression past the demographic portion of the survey (Figure 1). However, the total
number of responses for a particular question varied due to survey completeness and skip logic.
Demographic information is summarized in Table 2. The majority of ME/C respondents
practice in the United States (US) (90%, n=54/60), although responses were also collected from
Australia (n=3/60), New Zealand (n=1/60), Belgium (n=1/60) and Canada (n=1/60). Responses were
collected from ME/Cs practicing in 24 US states, with the majority of representation from California,
Washington state, Ohio, and New York (Appendix A: Table A1). Eighty-five percent (n=51/60) of
respondents identified as NAME members and most worked at a state- or county-owned facility
(75%, n=42/60). A doctor of medicine or doctor of osteopathic medicine was the highest degree held
by 85% (n=51/60). Fifty-five percent (n=33/60) identified as a medical examiner or forensic
pathologist. Respondents reported seeing a median of 2 TAD cases in the past year (range: 0-25; IQR:
3) and a median of 8 cases in the past 5 years (range: 0-100; IQR: 10).
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Figure 1. Survey Responses used in analysis. 97 total responses were collected, but after exclusions
due to respondents not confirming that they actively involved in autopsies or proceeding past
demographic questions, 60 responses were analyzed in this study.
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Table 2. Demographics of Survey Respondents
Responses

% (n)

Country
United States
Non-US

90.00 (54)
10.00 (6)

NAME
IACME
Both
Neither

75.00 (45)
13.33 (8)
10.00 (6)
1.67 (1)

State or County Owned
Academic Center
Academic/State
Private
Other

70.00 (42)
10.00 (6)
5.00 (3)
8.33 (5)
6.67 (4)

MD/DO and PhD
MD/DO
DDS
MBBS
MS
BA/BS

3.33 (2)
81.67 (49)
1.67 (1)
3.33 (2)
1.67 (1)
5.00 (3)

Organization

Facility

Highest degree

AAS
Other

1.67 (1)
1.67 (1)

Job Title(s)
Medical Examiner
Coroner
Forensic Pathologist
Other
Number of thoracic aortic dissection seen on autopsy
Cases seen last year
Cases seen over past 5 years
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50.00 (30)
18.33 (11)
60.00 (36)
5.00 (3)
n (median, min-max, IQR)
59 (2, 0-25, 3)
59 (8, 0-100, 10)

Legend: Demographic information reported by respondents (n=60). Highest degree was chosen from
all degrees attained. Respondents were able to select one or more relevant job titles, with the use of
each title reported in aggregate. Abbreviations: US United States; NAME National Association of
Medical Examiners; IACME International Association of Coroners and Medical Examiners; MD
Doctor of Medicine; DO Doctor of Osteopathic Medicine; PhD Doctor of Philosophy; DDS Doctor of
Dental Surgery; MBBS Bachelor of Medicine; Bachelor of Surgery; MS Master of Science; BA
Bachelor of Arts; BS Bachelor of Science; AAS Associate of Applied Science; Min minimum; Max
maximum; IQR inter-quartile range
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Postmortem genetic testing protocol for fatal thoracic aortic dissection
Fifty percent (n=27/54) of ME/Cs who collect samples for genetic testing reported that they
order postmortem genetic testing if TAD is diagnosed on autopsy and 51% (n=29/56) collect a
sample for genetic testing regardless of the decedent’s age and sex. Others acknowledged agespecific cut-offs they use to inform their decision to collect a specimen for genetic testing. Notably,
5.3% (n=3/56) of respondents only collect a sample from decedents below age 30, which is not
consistent with NAME’s guidelines to collect from anyone age 40 and below. Additionally, 12%
(n=7/56) never collect a sample or did not know at what age a sample is collected (Table 3).
Most ME/Cs who order genetic testing disclose all types of test results issued by the
laboratory to the decedent’s next-of-kin (NOK) (76%, n=20/26): positive results consistent with the
identification of a pathogenic variant, negative test results, and variants of uncertain significance
(VUS), which describe genetic variants with insufficient evidence to determine pathogenicity. Test
result disclosure protocols differed by result type for other respondents as some report only positive
results (7.7%, n=2/26), positive and VUS results (7.7%, n=2/26), or positive and negative results
(3.8%, n=1/26). Only one respondent who orders genetic testing does not report genetic testing
results to NOK (3.8%). Moreover only 39% (n=22/56) reported having access to a genetic counselor.
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Table 3. Genetic Service Capabilities and Practices
Responses
% (n)
Access to genetic counselor (n=56)
Yes, I have access to a genetic counselor 39.28 (22)
No, I do not have access to a genetic counselor 60.71 (34)
Sample collection for male decedent (n=56)
Below 30 years
5.36 (3)
Below 40 years 17.86 (10)
Below 50 years 10.71 (6)
Below 60 years
1.79 (1)
I collect samples regardless of age 51.79 (29)
I do not collect samples for males for genetic testing
3.57 (2)
I do not know
8.93 (5)
Sample collection for female decedent (n=56)
Below 30 years
5.36 (3)
Below 40 years 17.86 (10)
Below 50 years
8.93 (5)
Below 60 years
3.57 (2)
I collect samples regardless of age 51.79 (29)
I do not collect samples for females for genetic testing
3.57 (2)
I do not know
8.93 (5)
Ordering genetic testing for TAD (n=54)
Yes, I order genetic testing 50.00 (27)
No, I do not order genetic testing 50.00 (27)
Type of result disclosed (n=26)
Positive, Negative, and VUS 76.9 (20)
Positive and VUS
7.7 (2)
Positive and Negative
3.8 (1)
Positive only
7.7 (2)
Does not disclose results
3.8 (1)
Legend: Genetic counselor access, sample collection, genetic testing ordering, and genetics results
disclosure practices reported by respondents. Abbreviations: TAD thoracic aortic dissection; VUS
variant of uncertain significance
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Clinical Vignettes
Using a sliding VAS for three clinical vignettes, respondents were asked how likely they
were to perform a given action, from never to always. Individuals’ scores, representing the percent
chance they would perform a certain action, were compared between vignettes. Median VAS scores
are summarized for each clinical vignette (Table 4), with statistical analyses reported in Appendix A
Table A2. For the two vignettes with a young decedent, the 30 year-old TAD case with syndromic
features (vignette 1) and the 27-year-old non-syndromic TAD case (vignette 3), ME/Cs were
significantly more likely to perform all proposed actions (questions 1-7) compared to the 72-year-old
non-syndromic TAD case (vignette 2) (p<0.05). Specifically, the majority of respondents report that
they would always collect a biological sample for genetic testing for vignette 1 (73% n=42/57) and
vignette 3 (78.18%; n=43/55) compared to only 56% for vignette 2 (n=32/57). Further, ME/Cs’
behaviors were similar for both the early-onset syndromic case (vignette 1) and the early onset nonsyndromic case (vignette 3) with regard to how likely they were to order genetic testing. However,
respondents were more likely to provide information to relatives about increased risk for TAAD
(question 3) and refer relatives for genetic counseling (question 7) in the early-onset syndromic case
(vignette 1) than the early-onset non-syndromic case (vignette 3) (p = 0.0006, p=0.0285,
respectively). ME/C’s were asked how suspicious they were for a genetic cause of TAD for each
clinical vignette (question 8). Respondents were significantly more suspicious of a genetic cause in
the 30-year-old case with pectus carinatum, long fingers and other systemic features suggestive of
Marfan syndrome (vignette 1) compared to the 72-year-old non-syndromic case (vignette 2) and the
27-year-old non-syndromic case (vignette 3) (p<0.0001, p=0.0001, respectively). However,
respondents were still more suspicious for a genetic cause in the early-onset non-syndromic case
(vignette 3) compared to the later-onset non-syndromic case (vignette 2) (p<0.0001).
We elicited the number of TAD cases respondents reported in their office within the last year
or 5 years to evaluate the effect of ME/Cs’ experience performing autopsies on TAD cases. The
number of cases seen by ME/Cs was not significantly associated with how likely they were to
14

perform certain actions (questions 1-7) nor how suspicious they were for a genetic cause (question 8)
across vignettes (Appendix A: Table A2). Similarly, responses were not significantly different based
on whether or not the respondent orders genetic testing in practice, except in question 5, where
respondents who order genetic testing in practice were significantly more likely to order genetic
testing in the early-onset syndromic case (vignette 1) and the early-onset non-syndromic case
(vignette 3).
Access to a genetic counselor impacted actions taken by ME/Cs for the early-onset syndromic
case (vignette 1) and the early-onset non-syndromic case (vignette 3). In the early-onset syndromic
case (vignette 1), those who had access to a genetic counselor were significantly more likely to
collect a sample (question 1; p=0.0125), collect family history from relatives (question 2; p=0.0362),
and provide information to relatives about an increased risk for TAAD (question 3; p=0.0401). This
was different from the early-onset non-syndromic case (vignette 3), where those who had access to a
genetic counselor were significantly more likely to order genetic testing (question 5; p=0.045), refer
relatives for a cardiology evaluation (question 6; p=0.0134), or refer relatives for genetic counseling
(question 7; p=0.0067). However, genetic counselor access did not impact ME/Cs’ behaviors
regarding their actions or level of genetic suspicion for the 72-year-old TAD case (Appendix A:
Table A2).
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Table 4. Summary of Clinical Vignette Visual Analog Scale Responses
Vignette 1: Early-onset, Vignette 2: Later-onset,
Syndromic (Marfan)
Non-syndromic
Median (min-max;
Median (min-max;
Question
n
IQR)
n
IQR)
1. Collect a
57
100 (0-100; 1)
57
100 (0-100; 88)
biological sample
for genetic testing
2. Collect
additional family
60 100 (0-100; 24.5) 59
79 (0-100; 90)
history from
relatives
3. Provide
information to
relatives about
60
100 (0-100; 19)
56
20 (0-100; 92.5)
increased risk for
TAAD
4. Recommend
thoracic aortic
57
0 (0-100; 76)
55
0 (0-100; 1)
imaging for first
degree relatives
5. Order genetic
testing for the
57
5 (0-100; 72)
55
0 (0-100; 1)
deceased person
6. Refer relatives
for cardiology
56
90 (0-100; 96.5)
55
0 (0-100; 26)
evaluation
7. Refer relatives
for genetic
56
75 (0-100; 100)
54
0 (0-100; 9)
counseling
8. Suspicion for a
60 97 (30-100; 15.5) 54
17.5 (0-100; 25)
genetic cause

Vignette 3: Early-onset,
Non-syndromic
Median (min-max;
n
IQR)
55

100 (0-100; 0)

56

100 (0-100; 17)

53

100 (0-100; 50)

52

0 (0-100; 66)

54

2.5 (0-100; 96)

52

61 (0-100; 100)

52

45 (0-100; 100)

55

80 (40-100; 35)

Legend: Median visual analog scale (VAS) scores for the eight questions posed in each vignette.
VAS scores indicate the likelihood that an individual would do the action in question or the level of
suspicion for a genetic cause with 0 being “never” or “no suspicion” and 100 being “always” or
“definite genetic cause”. Abbreviations: Min minimum; Max maximum; IQR inter-quartile range;
TAAD thoracic aortic aneurysm or dissection
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Barriers to ordering genetic testing
Respondents identified several barriers to ordering postmortem genetic testing for TAD cases
(Table 5). Cost was the most frequently reported barrier with 42 of 55 (76%) respondents selecting it
as a barrier and 36 of 51 individuals (70.6%) ranking it as the number one barrier. The next most
common barrier selected was difficulty in contacting NOK of the decedent (n=11/55). Sixteen percent
of respondents (n=9/55) reported that there were no barriers to genetic testing; these individuals were
significantly more likely to have access to a genetic counselor (p=0.021). Collectively, issues
surrounding genetic testing information were listed as barriers by 50.9% (n=28/55), specifically,
difficulty finding an appropriate lab, not knowing what test to order, not knowing how to order
genetic testing, and lack of information to provide to NOK.
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Table 5. Barriers to Ordering Genetic Testing for a Deceased Person
Barriers

% (n)

Financial
Cost of genetic testing
Inability to obtain insurance coverage

76.36 (42)
16.36 (9)

Inability to collect samples for genetic testing
Difficulty finding an appropriate lab
Do not know what test to order
Do not know how to order genetic testing

5.45 (3)
16.36 (9)
14.54 (8)
12.72 (7)

Testing

Next-of-kin
Difficulty in contacting next-of-kin of the deceased person
Inability to get informed consent from next-of-kin
Lack of information to provide next-of-kin
Staff
Insufficient staffing
Lack of time
Lack of geneticists and/or genetic counselors in your area
Other
I do not see any barriers to genetic testing for a deceased person

20.00 (11)
16.36 (9)
7.27 (4)
7.27 (4)
7.27 (4)
10.90 (6)
14.54 (8)
16.36 (9)

Legend: Barriers to genetic testing for a deceased reported by respondents (n=55). Respondents
could select one or more barriers as applicable.
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Lack of information to provide next-of-kin
Inability to collect samples for genetic testing
Insufficient staffing
Do not know what test to order
Lack of time
Lack of geneticists and/or genetic counselors in your area
Inability to get informed consent from next-of-kin
Do not know how to order genetic testing
Inability to obtain insurance coverage
Difficulty finding an appropriate lab
I do not see any barriers to genetic testing for a deceased person
Difficulty in contacting next-of-kin of the deceased person
Other
Cost of genetic testing
0
Ranked 1st

5

Ranked 2nd

10

15

20

25

30

35

Ranked 3rd

Figure 2. ME/Cs rankings of their top three barriers to genetic testing for a deceased person ordered by
total combined frequency of selection (n=51)
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40

Alignment of practices with NAME guidelines
Respondents’ reported practices regarding sample collection, handling, and interactions with
NOK in reference to genetic testing are summarized in Table 6. Sample collection protocols were largely
consistent with guidelines established by NAME, as the majority of respondents collect whole blood
(90.7%, n=49/54) in a purple top tube (K2 EDTA) (95.9%, n=47/49) for all individuals under the age
of 40 years (82.1%, n=46/56). Regarding biospecimen storage and shipping protocols, respondents’
current practices were more varied in their alignment with NAME recommendations, ranging from
36-53%. Finally, respondents’ practices were least consistent with guidelines when it came to
obtaining informed consent from families (38%, n=10/26), checking with families about religious and
cultural objections (29%, n=16/54) and informing families of DNA banking options (24%, n=13/53).
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Table 6. Alignment of Reported Practices for Genetic Services with NAME Guidelines
Recommendation

% (n)

Sample collection
Sample collection age (<40 years) (n=56)
Sample type (whole blood) (n=54)
Blood tube (Purple top [K2 EDTA]) (n=49)

82.14 (46)
90.7 (49)
95.9 (47)

Sample handling
Sample stored <1 month (4°C) (n=46) 41.3 (19)
Sample stored >1 month (-20°C to -70°C) (n=49) 53.06 (26)
Fresh sample shipping (overnight at room temperature) (n=26) 46.15 (12)
Frozen sample shipping (overnight on dry ice) (n=25) 36.00 (9)
Interactions with next-of-kin
Obtaining informed consent (n=26) 38.46 (10)
Informing families of DNA banking options (n=53) 24.53 (13)
Checking with families about religious and cultural objections (n=54) 29.63 (16)
Legend: Percent of respondents whose survey answers were compliant with NAME guidelines for the
given category. The NAME guidelines regarding sample collection and sample handling are noted in
parentheses. Abbreviations: NAME National Association of Medical Examiners; EDTA
ethylenediaminetetraacetic acid
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Discussion
With high mortality rates and many individuals failing to reach the hospital in cases of TAD,
ME/Cs are in a unique position to recognize cases at high risk for having a heritable form of disease
and play a role in providing genetic counseling and testing, either directly or through referral (1-4). In
the context of fatal TAD diagnosed by autopsy, a positive genetic test result will determine the cause
of dissection and enable the identification of relatives at-risk for dissection through subsequent
cascade genetic testing. The clinical utility of genetic testing for TAD has expanded extensively over
the past decade as more aortic disease genes have been identified and technological advances enabled
more accessible testing by reducing cost. Indications for genetic testing now extend beyond cases of
suspected Marfan or Loeys-Dietz syndromes as 11 genes have been established to be strongly
associated with TAAD with or without syndromic features (10). Here we sought to investigate the
clinical factors that may currently contribute to a ME/C’s suspicion for hereditary TAD and describe
their practices with regard to postmortem genetic testing and counseling.
Several clinical determinants should raise suspicion for a genetic component to TAD; namely,
an early age at diagnosis (< 60 years), a family history of TAAD or sudden death, and/or the presence
of physical features (deemed “syndromic”) associated with Marfan syndrome or, Loeys-Dietz
syndrome. In this study, we did not ask respondents to propose a diagnosis for the decedent in any of
the vignettes; however, ME/Cs appeared to recognize the syndromic features described in the vignette
1, which included pectus carinatum, arachnodactyly, and tall stature. Our intent was for these features
to be suggestive of Marfan syndrome; however they also overlap with features of Loeys-Dietz
syndrome so ME/Cs may have appropriately included this in their differential diagnosis. Regardless,
respondents were significantly more suspicious of a genetic cause and more likely to refer the family
for genetic counseling for this early-onset syndromic case (vignette 1) than they were for either the
later-onset (vignette 2) or the early-onset (vignette 3) non-syndromic cases. In addition, age appeared
to be a driving factor for some actions taken by ME/Cs. Across all vignette questions examining
collection, referral, ordering, and information-giving practices, respondents were more likely to
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perform these actions for the early-onset decedents both with (vignette 1) and without (vignette 3)
syndromic features, compared to the later-onset non-syndromic decedent (vignette 2). This suggests
that respondents recognize that both early age of diagnosis and syndromic physical characteristics are
concerning for an underlying genetic etiology and should prompt genetic counseling and testing.
Highly penetrant pathogenic variants in eleven genes are confirmed to confer a risk for TAD;
however, absence of a pathogenic variant in one of these does not eliminate genetic risk. While
environmental factors, such as illicit drug use or hypertension, are associated with TAD and could be
at play in a case with negative genetic testing, they do not preclude a genetic cause (3, 4, 19).
Additionally, it is unlikely that all the genes predisposing to heritable TAD have been identified. For
these reasons, the AHA/ACC guidelines for the diagnosis and management of TAAD patients
recommend aortic imaging for first-degree relatives of all cases of TAAD regardless of age (15).
Similar to cascade genetic testing, imaging of at-risk relatives promotes the identification of
asymptomatic aortic aneurysms at an early stage, which can be repaired in a timely manner to prevent
an acute dissection. However, for maximum efficacy in the postmortem setting, this requires
collection of family history and communication with NOK by the ME/C, or referral to an appropriate
healthcare provider. Involvement of ME/Cs in genetic testing and risk communication to relatives of
the decedent has previously been explored, but has primarily centered on so-called “autopsy
negative” conditions like cardiac arrhythmias (20-24). In our study, ME/Cs were more likely to
perform these tasks in the early-set TAD cases than in the later-onset case. Regardless of the case at
hand, median VAS scores indicate that ME/Cs would collect family history and provide information
to NOK about an increased risk for TAAD, but the final step of referring NOK for a cardiology
evaluation or recommending thoracic aortic imaging is less common. While the reason for this
discrepancy was not explored, an issue complicating referral may be that communication with NOK
to provide this complete care is not always easy. The second most commonly identified barrier was
difficulty in contacting NOK. While this barrier was only listed by 20% of respondents, it represents
a real issue in the delivery of results and obtaining follow-up care for NOK. Uptake of cascade
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genetic testing already presents a challenge with only a 7-30% uptake in other studies (23, 24). Thus,
having the ability to make direct contact, employ online educational tools, or use other means of
communication with families is crucial to improve uptake of cascade genetic testing.
The importance of involving a multidisciplinary team that includes genetic counselors in
postmortem genetic evaluations has been established and was further supported by ME/C responses
in our study (25-27). Significant differences in participant responses were observed between those
who had access to a genetic counselor and those who did not, indicating that genetic counselor access
may impact actions and recommendations made by ME/Cs. For example, respondents who had access
to a genetic counselor were more likely to order genetic testing (question 5), refer to cardiology
(question 6), and refer to genetic counseling (question 7) for the early-onset non-syndromic decedent
(vignette 3). While our study was not designed to evaluate knowledge regarding hereditary TAD, it
may be that ME/Cs who have access to a genetic counselor are better informed regarding the features
that should prompt genetic testing and how to execute the genetic testing process. Data from the
cardiology setting indicate that genetic counselors aid in appropriate test selection, identify
appropriate testing candidates, and provide appropriate follow-up care including genetic test result
disclosure (27). In our study ME/Cs level of comfort with delivering genetic test results was not
directly assessed, but with 76% of ME/Cs who order genetic testing disclosing all result types
(positive, negative, variant of uncertain significance) to NOK (n=20/26) it is important that they have
access to genetics professionals when needed. The benefits of this is further supported as respondents
in our study who reported experiencing no barriers to genetic testing were significantly more likely to
have access to a genetic counselor. Currently, genetic counselors are accessible remotely with recent
studies finding that up to 68% of genetic counselors have participated in telemedicine, both as part of
hospital systems as well as through companies specifically designed to provide genetic telehealth
services, demonstrating that genetic counselors do not need to be a direct part of an ME/C’s home
institution to assist both the provider and the NOK (28).
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Historically, genetic testing cost and/or insufficient insurance coverage has been a pervasive
barrier to providing genetic services, even when medical guidelines support its utility. However, over
the last five years, the industry has seen a dramatic reduction in cost, enabling increased access to
genetic testing for individuals in all settings, including postmortem (29, 30). Yet, our study
demonstrates that cost of genetic testing remains a major concern, as it was the most frequently
identified barrier by 76% of respondents and top-ranked by 70%. This is higher than a previous study
of medical examiners in Europe, which reported that 30.9% believed the cost of genetic testing was
too high (20). It is worth noting that studies predating 2014 that investigated insurance coverage in
the US for postmortem genetic testing reported very limited coverage; however, more recent data
demonstrate coverage has improved (14, 31, 32). Therefore, the perceived cost barrier reported by our
respondents may be both influenced by a lack of updates on recent improvements in payor coverage
for postmortem testing and the healthcare payor system in the U.S., where the majority of our
respondents practice (n=54/60). Moreover, ME/Cs may not be aware of more recent alternative
payment options for genetic testing through many commercial laboratories, which provide lower-cost
testing for those without insurance (D. Angeles, personal communication, March 2, 2020). Additional
barriers to genetic testing were noted but appeared to be less impactful. Encouragingly, the ability to
focus on one or two meaningful barriers will allow for targeted studies in the future and focused
implementation of solutions.
Professional medical society guidelines in forensics and cardiology provide an important
foundation and resource for practitioners to provide care for individuals with families with TAAD. In
2013, NAME published recommendations regarding the storage and collection of biospecimens for
postmortem genetic testing, which were used to shape questions in this study (14). Overall,
respondents demonstrated a good understanding of the appropriate age for genetic testing and best
sample type to collect for that purpose, with 51% reporting that they would collect a sample for
anyone with TAD regardless of age, and 90% appropriately collecting whole blood. However, there
was a wider range of practices regarding the handling of samples after collection, such as the proper
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temperatures to ship and/or store samples. While the NAME guidelines established general
recommendations for postmortem specimen collection and handling, individual laboratories may have
specific recommendations and should be considered. Lastly, respondents reported that they rarely
contact NOK to obtain consent or discuss DNA banking options. Obtaining consent is not required by
law in public autopsies, which may impact the likelihood of ME/Cs seeking informed consent from
NOK (33). Furthermore, these reduced frequencies of contacting NOK about consent or DNA
banking may not represent a lack of effort, as the second most common barrier reported was
difficulty in contacting NOK. Overcoming these challenges will be crucial to ensuring that families
are informed about their increased dissection risk and receive appropriate medical intervention.
This survey garnered a relatively low response rate, which did not enable us to model the data
and determine the factors influencing ME/Cs decisions to engage in the proposed actions in the
clinical vignettes. However, because the study topic was specific to fatal cases of TAD and dispersed
to a busy provider cohort of ME/Cs, 60 useable response was adequate to establish trends with
baseline data. It is possible that a low volume of TAD cases presenting to an ME/C’s office dissuaded
some from responding. More members of NAME responded than IACME, which likely led to lower
responses from ME/Cs outside the US; therefore, findings cannot be generalized to reflect ME/Cs’
practices globally. Additionally, using VAS scores allowed for more flexibility in participants’
responses; however, respondents were not permitted to return to previous vignettes to modify their
answers. Therefore, if an individual answered “100” for a particular question, meaning they always
perform a particular task, their answer for the same question in subsequent vignettes could only stay
the same or decrease, despite if a respondent determined they were more likely to do that task in a
future vignette. This limitation may result in some discrepancies when analyzing the difference in
responses for an individual between vignettes. Finally, responses were obtained by self-report, were
not confirmed by medical record review, and therefore, subject to recall bias.
With thousands of deaths from acute aortic dissection every year, ME/Cs will continue to be
among the first line of practitioners to evaluate these decedents and interact with their families.
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Through a series of clinical vignettes, we demonstrate that ME/Cs appear to recognize the need for a
genetic testing and evaluation in young patients with TAD. The likelihood of ordering genetic testing
or providing further information and referrals to family members was impacted not by clinical
experience, but by access to a genetic counselor, hinting at the importance of establishing
multidisciplinary teams to provide care. Additional barriers to genetic testing exist, most notably cost
and communication with NOK. Guidelines established by NAME provide a foundation for
establishing appropriate postmortem testing protocols for TAD, and while many ME/Cs’ practices
align with sample collection and storage guidelines, there remains a gap regarding communication
with NOK to provide informed consent and options for genetic testing. Moving forward, this study
provides a basis for the investigation of clinical strategies to improve communication with NOK, to
establish resources to assist with ME/C access to genetic services, and to increase ME/Cs’ ability to
take the necessary actions to diagnose the TAD decedent and aid their family. As syndromic features
are not always present and family history information is not always available it would be reasonable
to collect samples for genetic testing or DNA banking in all TAD cases given the established genetic
component and the implications of identifying it. In addition, all first-degree relatives should be
referred to genetic counseling and cardiology for appropriate screening and testing. Finally, based on
the initial barriers identified in our study, future research could further examine those barriers with
the aim of establishing programs or resources to aid ME/Cs in identifying affordable gene tic testing
and providing NOK with the appropriate care and referrals.
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Appendix A: Additional Data
Table A1. State in which ME/C currently works
State
n (%)
Arizona
2 (3.7)
Arkansas
1 (1.85)
California
6 (11.11)
Colorado
2 (3.7)
Connecticut
3 (5.56)
Florida
3 (5.56)
Hawaii
1 (1.85)
Idaho
2 (3.7)
Illinois
2 (3.7)
Iowa
1 (1.85)
Kentucky
1 (1.85)
Maine
1 (1.85)
Michigan
3 (5.56)
Missouri
2 (3.7)
Nevada
1 (1.85)
New Jersey
1 (1.85)
New York
4 (7.41)
Ohio
5 (9.26)
Pennsylvania
3 (5.56)
Texas
2 (3.7)
Vermont
1 (1.85)
Washington
5 (9.26)
Wisconsin
1 (1.85)
Wyoming
1 (1.85)
Legend: States reported by respondents as their current employment location (n=60)
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Table A2. P-values from several statistical tests comparing visual analog scores amongst vignettes or between distinct groups of respondents
Test
Question
1

Question
2

Question
3

p-value
Question
Question
4
5

0.0005*
0*
0.2169

0.0001*
0*
0.207

0*
0*
0.0006*

0.0024*
0.0004*
0.9045

0.7336
0.9028
0.7306
0.4228
0.6419
0.1171

0.2349
0.2562
0.1181
0.0799
0.7421
0.1384

0.1449
0.26
0.8946
0.4739
0.6707
0.8409

0.0125*
0.2485
0.0541
0.9516
0.804
0.6317

0.0362*
0.0524
0.0717
0.8711
0.5784
0.8748

0.0401*
0.0816
0.1047
0.1889
0.6139
0.6093

Question
6

Question
7

Question
8

0*
0*
0.079

0*
0*
0.058

0*
0*
0.0285*

0*
0*
0.0001*

0.1234
0.6223
0.098
0.0752
0.9742
0.1568

0.2787
0.5687
0.3454
0.856
0.7018
0.925

0.5901
0.3878
0.4563
0.4995
0.7853
0.9698

0.572
0.2578
0.7303
0.4755
0.6133
0.7352

0.4933
0.6736
0.1041
0.9114
0.6125
0.4739

0.606
0.9338
0.9164
0.2786
0.4646
0.6176

0.0826
0.94
0.045*
0.0014*
0.4624
0.0014*

0.1033
0.7995
0.0134*
0.7812
0.0500
0.8442

0.0524
0.981
0.0067*
0.9923
0.1254
0.4608

0.1621
0.7726
0.2358
0.4264
0.1656
0.5781

Sign-rank
Vignette 1 vs vignette 2
Vignette 2 vs vignette 3
Vignette 1 vs vignette 3
Kruskal-Wallis with Dunn test
Vignette 1 by number of cases seen in 1 year
Vignette 2 by number of cases seen in 1 year
Vignette 3 by number of cases seen in 1 year
Vignette 1 by number of cases seen in 5 years
Vignette 2 by number of cases seen in 5 years
Vignette 3 by number of cases seen in 5 years
Mann-Whitney U
Vignette 1 by Access to a genetic counselor
Vignette 2 by Access to a genetic counselor
Vignette 3 by Access to a genetic counselor
Vignette 1 by Order genetic testing
Vignette 2 by Order genetic testing
Vignette 3 by Order genetic testing
* = Significant p-value using α level of 0.05

Appendix B: Survey Invitation
You are invited to take part in a research study called, “Genetic Testing and Counseling for Fatal Cases
of Acute Aortic Dissections”, conducted by Bradley Power, BA of the University of Texas Health
Science Center at Houston. Dianna Milewicz, MD, PhD is the principal investigator. The purpose of this
study is to evaluate medical examiners’ practices and perceived barriers surrounding genetic testing and
counseling in cases of thoracic aortic dissection. The purpose of this survey is not to assess for correct
answers; answers will only be analyzed and reported in aggregate.
If you decide to take part in the study, the total time commitment is 15-20 minutes. You are invited to
take part in this study because you are a member of the National Association of Medical Examiners
(NAME) and/or the International Association Coroners and Medical Examiners (IACME). Participation
in this study is voluntary and you may choose to stop taking the survey at any time. Of note, two of the
questions involve data retrieval that may not be possible if you take the survey outside of your place of
employment.
If you agree to take part in this study, the information you provide will help determine current practices
and barriers surrounding post-mortem genetic testing ordered by medical examiners and coroners. You
may not receive any benefit from taking part in this study. Possible risks are limited to breach of
confidentiality. The information collected in the survey will not be used to identify participants and will
be kept on a secure server.
There is no cost to participate and you will not be paid to take part in this study. You will not be
personally identified in any reports or publications that may result from this study. Any personal
information about you that is gathered during this study will remain confidential to every extent of the
law. If you have any questions about this project please contact Bradley Power or Alana Cecchi, MS,
CGC at 713–500-6715.
Proceeding with the survey implies that you have read and understand your rights and that you consent to
participate in the study.
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Appendix C: Survey Questions
Instructions: This survey contains questions about thoracic aortic aneurysms and dissections in the form
of clinical vignettes and questions related to your current work practices. If you have already completed
this survey, please exit now. Thank you for your time.
2. I am a member of ...
o

National Association of Medical Examiners (NAME)

o

International Association of Coroners and Medical Examiners (IACME)

o

Both

o Neither
3. What country do you work in?
▼ United States of America ... Zimbabwe
Skip To: Q5 If List of Countries = United States of America
4. What city(ies) do you serve?
Skip To: Q7 If Condition: What city(ies) do you serve? Is Not Empty. Skip To: What type of institution do
you work ....
5. In which state do you currently work?
▼ Alabama ... I do not reside in the United States
6. What county(ies) do you serve? For those who work in Louisiana, please enter parish name(s). For
those who work in Alaska or New York City, please enter borough name(s).
7. What type of institution do you work at? (Check all that apply)
▢ Academic center
▢ Private Facility
▢ State or county owned facility
▢ Other (Please specify)
8. Are you currently actively involved in performing autopsies?
o

Yes

o

No

Skip To: End of Survey If Are you currently actively involved in performing autopsies? = No
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9. What degrees have you attained? (Check all that apply)
▢ BA/BS
▢ MS
▢ PhD
▢ MD/DO
▢ DPT
▢ DDS
▢ JD
▢ Other (Please specify)
10. What is your job title? (Check all that apply)
▢ Medical Examiner
▢ Coroner
▢ Forensic Pathologist
▢ Other (Please specify)
Instructions: Please answer one of the following questions with an integer. The answer box will not
accept ranges.
11. How many cases of thoracic aortic dissection have you seen in the past year?
12. How many cases of thoracic aortic dissection have you seen in the past 5 years?
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Instructions: The following are three clinical vignettes describing a potential case. Please read the
vignette and respond to the following questions.
Vignette 1: A 30-year-old man dies suddenly at home. On post-mortem exam, he is 6’ 8”, thin, has a
mild pectus carinatum and long, thin fingers. His medical record notes scoliosis. On autopsy, he is found
to have type A aortic dissection with pericardial tamponade.
On a scale from “I would always perform that task” to “I would never perform that task,” how likely
would you be to carry out the following tasks for this case? Please move the slider to register your
response.

Never
0

25% of the
time
25

50% of the
time
50

75% of the
time
75

Always
100

I or someone in my office would collect
a biological sample from the deceased
person that could be used for genetic
testing.
I or someone in my office would attempt
to collect additional family history from
relatives.
I or someone in my office would
provide information to the deceased
person’s relatives about an increased
risk for thoracic aortic aneurysms and
dissections.
I or someone in my office would
recommend thoracic aortic imaging for
first degree relatives of the deceased
person.
I or someone in my office would order
genetic testing for the deceased person.
I or someone in my office would refer
the deceased person’s relatives for
cardiology evaluation.
I or someone in my office would refer
the deceased person’s relatives for
genetic counseling.

Based on the information provided, how suspicious are you that there is a genetic cause for Vignette 1?
No suspicion
0
10

20

30

Somewhat suspicious
40
50
60
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70

80

Highly suspicious
90
100

Vignette 2: A 72-year-old man complains of chest pain and dies suddenly in a restaurant. On postmortem exam, he is 5’9” with average body habitus. His medical record indicates he was healthy except
mild hypertension treated with one drug. On autopsy, he is found to have type A aortic dissection with
pericardial tamponade.
On a scale from “I would always perform that task” to “I would never perform that task,” how likely
would you be to carry out the following tasks for this case? Please move the slider to register your
response.

Never
0

25% of the
time
25

50% of the
time
50

75% of the
time
75

Always
100

I or someone in my office would collect
a biological sample from the deceased
person that could be used for genetic
testing.
I or someone in my office would attempt
to collect additional family history from
relatives.
I or someone in my office would
provide information to the deceased
person’s relatives about an increased
risk for thoracic aortic aneurysms and
dissections.
I or someone in my office would
recommend thoracic aortic imaging for
first degree relatives of the deceased
person.
I or someone in my office would order
genetic testing for the deceased person.
I or someone in my office would refer
the deceased person’s relatives for
cardiology evaluation.
I or someone in my office would refer
the deceased person’s relatives for
genetic counseling.
Based on the information provided, how suspicious are you that there is a genetic cause for Vignette 2?
No suspicion
0
10

20

30

Somewhat suspicious
40
50
60
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70

80

Highly suspicious
90
100

Vignette 3: A 27-year-old man collapses and dies suddenly after a run. On post-mortem exam, he is
5’9”, average body habitus, and the family reports he was healthy and had no medical problems. On
autopsy, he is found to have type A aortic dissection with pericardial tamponade.
On a scale from “I would always perform that task” to “I would never perform that task,” how likely
would you be to carry out the following tasks for this case? Please move the slider to register your
response.
25% of the
Never
time
0
25

50% of the
time
50

75% of the
time
75

Always
100

I or someone in my office would collect
a biological sample from the deceased
person that could be used for genetic
testing.
I or someone in my office would attempt
to collect additional family history from
relatives.
I or someone in my office would
provide information to the deceased
person’s relatives about an increased
risk for thoracic aortic aneurysms and
dissections.
I or someone in my office would
recommend thoracic aortic imaging for
first degree relatives of the deceased
person.
I or someone in my office would order
genetic testing for the deceased person.
I or someone in my office would refer
the deceased person’s relatives for
cardiology evaluation.
I or someone in my office would refer
the deceased person’s relatives for
genetic counseling.
Based on the information provided, how suspicious are you that there is a genetic cause for Vignette 3?
No suspicion
0
10

20

30

Somewhat suspicious
40
50
60

35

70

80

Highly suspicious
90
100

13. Do you have access to a genetic counselor?
o

Yes, I have one I can contact and/or refer to.

o

Yes, I have one I can contact and they work at my institution.

o

No, I do not have one I can contact, but I know how to find one.

o

No, I do not have one I can contact and I do not know how to find one.

14. Are there any additional services you would provide for the deceased person or next-of-kin in the
above vignettes? e.g. referral to research studies
o

Yes (Please specify)

o

No

Instructions: The following questions apply to cases of thoracic aortic dissection or aneurysm.
15. At what age of death do you collect samples for genetic testing in males?
o

Below 80 years

o

Below 70 years

o

Below 60 years

o

Below 50 years

o

Below 40 years

o

Below 30 years

o

Below 20 years

o

Below 10 years

o

I collect samples regardless of age.

o I do not collect samples for males for genetic testing in cases of thoracic aortic aneurysm or
dissection.
o

I do not know
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16. At what age of death do you collect samples for genetic testing in females?
o

Below 80 years

o

Below 70 years

o

Below 60 years

o

Below 50 years

o

Below 40 years

o

Below 30 years

o

Below 20 years

o

Below 10 years

o

I collect samples regardless of age.

o I do not collect samples for females for genetic testing in cases of thoracic aortic aneurysm or
dissection.
o

I do not know

Instructions: Please answer the following questions regarding sample collection practices for the
purpose of genetic testing. Questions about sample submission will follow.
17. When collecting a sample, do you check with next-of-kin about religious or cultural objections?
o

Yes

o

No

o

Sometimes

18. What samples do you collect? (Check all that apply)
▢ Hair
▢ Whole blood
▢ Skin
▢ Tissue (Please specify type of tissue)
▢ Blood card
▢ Muscle (non-cardiac)
▢ Other (Please specify)
Skip To: Q22 If What samples do you collect? (Check all that apply) != Whole blood
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19. When you collect whole blood, what type of tube(s) do you use? (Check all that apply)
▢ Purple top (K2 EDTA)
▢ Green top (sodium heparin)
▢ Royal blue top (no additive)
▢ Gold top (serum separator)
▢ Other (Please specify)
20. If the whole blood sample is kept for less than a month, at what temperature is the sample stored?
o

4°C

o

-20°C

o

-70°C or colder

o

I do not know

21. If the whole blood sample is kept for longer than a month, at what temperature is the sample
stored?
o

4°C

o

-20°C

o

-70°C or colder

o

I do not know

Instructions: In the following questions we define genetic testing as the clinical sequencing and/or
deletion/duplication analysis of genes associated with thoracic aortic aneurysms and dissections.
22. Do you ever order genetic testing?
o

Yes

o

No

Skip To: Q31 If Do you ever order genetic testing? = No
23. How do you ship fresh whole blood samples to a genetic testing laboratory?
o

Overnight in a Styrofoam container at room temperature

o

Overnight in a Styrofoam container with dry ice

o

Other (Please specify)
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24. How do you ship frozen whole blood samples to a genetic testing laboratory?
o

Overnight in a Styrofoam container at room temperature

o

Overnight in a Styrofoam container with dry ice

o

Other (Please specify) ________________________________________________

25. Do you or someone else in your office seek consent from the deceased person's next-of-kin for
genetic testing?
o

Yes

o

No

Skip To: Q27 If Do you or someone else in your office seek consent from the deceased person's next-ofkin for gen... = No

26. Which members of the office obtain consent from next-of-kin? (Check all that apply)
▢ I, myself, obtain consent.
▢ Social worker
▢ Genetic counselor
▢ Nurse
▢ Nurse Practitioner
▢ Physician’s assistant
▢ Other (Please specify)
27. Do you or someone else in your office disclose the results of genetic testing to next-of-kin?
o

Yes

o

No

Skip To: Q30 If Do you or someone else in your office disclose the results of genetic testing to next-ofkin? = No
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28. Which members of the office disclose genetic testing results to next-of-kin? (Check all that apply)
▢ I, myself, disclose genetic testing results.
▢ Social worker
▢ Genetic counselor
▢ Nurse
▢ Nurse Practitioner
▢ Physician’s assistant
▢ Other (Please specify) ________________________________________________
29. Which of the following type(s) of genetic testing results do you disclose to next-of-kin? (Check all
that apply)
▢ Positive results (gene mutation identified)
▢ Negative results (No gene mutation identified)
▢ Variants of uncertain significance
30. What financial means have you used to cover the cost of genetic testing? (Check all that apply)
▢ Paid out of pocket by next-of-kin
▢ Insurance of the deceased person
▢ Research grant
▢ The county government covers the full or partial cost of testing.
▢ The state government covers the full or partial cost of testing.
▢ The federal government covers the full or partial cost of testing.
▢ Testing is covered by the office budget
▢ I collect samples and refer to other healthcare providers to order genetic testing.
▢ Other (Please specify) ________________________________________________
31. Do you or someone else in your office inform the next-of-kin of options for DNA banking? Here we
define DNA banking as the long term storage of DNA for future analysis or testing.

o Yes
o No
Skip To: Q33 If Do you or someone else in your office inform the next-of-kin of options for DNA
banking? Here we... = No
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32. Which members of the office inform next-of-kin of DNA banking options? (Check all that apply)
▢ I, myself, inform the next-of-kin of DNA banking options.
▢ Social worker
▢ Genetic counselor
▢ Nurse
▢ Nurse Practitioner
▢ Physician’s assistant
▢ Other (Please specify)
33. What do you see as barriers to ordering genetic testing for a deceased person? (Check all that apply)
▢ Difficulty in contacting next-of-kin of the deceased person
▢ Do not know how to order genetic testing
▢ Inability to get informed consent from next-of-kin
▢ Inability to collect samples for genetic testing
▢ Difficulty finding an appropriate lab
▢ Lack of time
▢ Inability to obtain insurance coverage
▢ Do not know what test to order
▢ Cost of genetic testing
▢ Lack of information to provide to next-of-kin
▢ Insufficient staffing
▢ Lack of geneticists and/or genetic counselors in your area
▢ Other (Please Specify)
▢ I do not see any barriers to genetic testing for a deceased person.
Carry Forward Selected Choices - Entered Text from "What do you see as barriers to ordering genetic
testing for a deceased person? (Check all that apply)"
34. Please rank your top 3 barriers you selected from most important (1) to least important (3).

Display This Question:
If Do you ever order genetic testing? = No
35. Besides any barriers selected above, are there any other reasons you do not order genetic testing?
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Display This Question:
If At what age of death do you collect samples for genetic testing in males? = I do not collect
samples for males for genetic testing in cases of thoracic aortic aneurysm or dissection.
And If
At what age of death do you collect samples for genetic testing in females? = I do not collect
samples for females for genetic testing in cases of thoracic aortic aneurysm or dissection.
36. Besides any barriers selected above, are there any other reasons you do not collect samples for
genetic testing?
End of Survey
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